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Background and Objectives
Plasma-derived concentrates containing von Willebrand factor and factor VIII
(VWF/FVIII concentrates) are the mainstay of treatment of patients with inherited von
Willebrand’s disease (VWD) who are unresponsive or have a contraindication to
desmopressin (DDAVP) therapy. Only a few clinical studies are available on the use
of these VWF/FVIII concentrates in large numbers of cases and within the same coun-
try. The aim of our study was to collect retrospective data on the efficacy and safety
of Haemate®P (CSL Behring, Marburg, Germany) in a large cohort of well-character-
ized VWD patients after the introduction of the guidelines for VWD management in
Italy. 
Design and Methods
A retrospective survey of data records was organized among ten Italian Hemophilia
Centers in order to retrieve information on the clinical use of Haemate®P. Data on
100 VWD patients (44 males and 56 females, median age 41.5, range 2-87 years)
were available relating to the period from January 2002 to December 2004. All
patients were diagnosed according to the criteria proposed by the Italian guidelines
for VWD management. 
Results
Of the 100 VWD patients enrolled, 23 had type 1 VWD, 40 had type 2 (2A=7, 2B=11,
2M=9, 2M Vicenza=13) and 37 had type 3. Seventy-one percent were severely affect-
ed, as shown by VWF:RCo levels <10 IU/dL. Fifty-nine patients were treated with
Haemate® P because of 280 spontaneous bleeding episodes. These patients
required 1,003 infusions of Haemate®P with a median daily dose of 72 (27-135)
VWF:RCo IU/kg. In 95% of patients, clinical responses were rated as excellent/good.
Fifty-six patients underwent major surgery (n=17), minor surgery (n=28), invasive pro-
cedures (n=9) or dental procedures (n=19), with a total consumption of 1.97×106 IU
of VWF:RCo through 366 infusions of Haemate®P. The median daily dose was 80
(range, 27-146) VWF:RCo IU/kg, with clinical responses rated as excellent/good in
97% of patients. Twelve patients (type 1=1, type 2B=1, type 2M Vicenza=1, type 3=9,
with a median age of 34.5, range 11-71 years) also underwent 17 long-term second-
ary prophylaxis regimens to prevent recurrent bleeding at the same site (47% in the
gastrointestinal tract, 35% in joints). During the 4,358 days of prophylaxis, the
patients received 1,424 infusions of Haemate®P, given three times (53%) or twice
(47%) a week, with clinical responses rated as excellent/good in 100%. No serious
adverse events, including thrombosis, were reported in the 370 evaluated treat-
ments. 
Interpretation and Conclusions
Based on this retrospective study conducted in a large cohort of Italian patients
(n=100) and covering a long period of observation (36 months), Haemate® P was
shown to be effective and safe for the clinical management of patients with VWD,
whether given on demand or as prophylaxis.
Key words: von Willebrand’s disease, Haemate®P/Humate-P®, ristocetin
co-factor unit, bleeding, surgery, secondary long-term prophylaxis. 
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Von Willebrand’s disease (VWD), the most fre-quent inherited bleeding disorder, is caused byquantitative (types 1 and 3) or qualitative (type
2) defects of von Willebrand factor (VWF).1,2 The thera-
py objective for VWD is to correct the dual defects of
hemostasis, i.e. abnormal platelet adhesion and the
abnormal coagulation due to low factor VIII (FVIII:C).3
Two main therapeutic options are available: desmo-
pressin (DDAVP), which releases endogenous VWF
from endothelial cells, and exogenous VWF contained
in VWF/FVIII plasma-derived concentrates. VWF/FVIII
concentrates are indicated for patients with type 3
VWD, for patients with type 2B (since DDAVP can
induce transient thrombocytopenia) and, for all those
patients with types 1 and 2 VWD who are unresponsive
or who may have contra-indications to DDAVP.2,4
Plasma-derived VWF/FVIII concentrates suitable for
treatment of VWD should contain a relatively high
amount of VWF activity and some FVIII:C. They should
be tested before clinical use for their pharmacokinetics
and clinical efficacy in retrospective and prospective
clinical trials in relatively large numbers of VWD
patients.1-3 Among the several concentrates containing
VWF, only a few have been extensively evaluated in
pharmacokinetic trials as well as in retrospective or
prospective efficacy studies in VWD.5
Haemate® P/Humate® P, a pasteurized plasma-derived
VWF/FVIII concentrate widely used in VWD, is charac-
terized by a very high content of VWF (VWF:RCo IU,
2.4 for each IU of FVIII:C) with a relatively high per-
centage of large molecular weight VWF multimers.6-8
Haemate® P has also had an excellent safety record with
regards to blood-borne infections over the past 25 years
of clinical use.9-12
Clinical efficacy data were collected for Haemate® P
through a large retrospective study organized by the
Canadian Hemophilia Centers.13 Other published studi-
es include a retrospective analysis of the efficacy and
safety of Haemate® P in preventing bleeding during sur-
gery or invasive procedures in 26 Italian VWD
patients,14 as well as two prospective, multicenter,
open-label, non-randomized studies conducted in the
USA on Humate®-P used in urgent bleeding and urgent
surgical events.15,16
In this retrospective survey of ten Italian Hemophilia
Centers, we report the most updated information on the
clinical use of Haemate® P as collected in 100 patients
with VWD unresponsive to DDAVP who were given the
study drug because of spontaneous bleeds, for preven-
tion of bleeding during surgery, and also for secondary
long-term prophylaxis. This is the largest retrospective
clinical study in Italian VWD patients treated with the
same VWF/FVIII concentrate after the introduction in
2002 of the guidelines on VWD management by the
Italian Association of Hemophilia Centers (AICE).
Design and Methods
Study design 
The study is based on a retrospective collection of
clinical data from patients diagnosed with inherited
VWD and treated with Haemate® P to stop bleeds when
they occurred spontaneously (bleeds), to prevent exces-
sive bleeding during surgical procedures (surgery) and to
prevent the recurrence of bleeding at the same site (sec-
ondary long-term prophylaxis). The study involved
patients with VWD followed from January 2002 to
December 2004 (36 months) in ten Italian Hemophilia
Centers. The attending physicians were asked to collect
all the available data on the clinical situation leading to
treatment. Inclusion criteria consisted in the availability
of at least a minimum set of data: age, gender and body
weight, diagnosis and classification of VWD, indication
for treatment with VWF/FVIII concentrates (e.g. docu-
mented unresponsiveness or contra-indication to
DDAVP) detailed description of the bleeding episode or
surgical procedure and treatment outcome; the adminis-
tered dosage of concentrate and data on any other con-
comitant and adjuvant treatments (e.g. DDAVP, antifib-
rinolytic amino acids, and other transfusion therapies).  
Study product 
Haemate® P (CSL Behring, Marburg, Germany) is a
pasteurized plasma-derived VWF/FVIII concentrate
characterized by a high VWF activity (≥2,400 IU
VWF:RCo/1,000 IU FVIII:C) and by the relatively high
proportion of high molecular weight VWF multimers
when compared with other commercially available
VWF/FVIII concentrates.6-8  
Patients 
Patients were diagnosed according to the criteria of
the Scientific Standardization Committee on VWF of
the International Society for Thrombosis and
Haemostasis, approved by the Italian Association of
Hemophilia Centers (AICE)2 to which the ten Centers
participating in this study are affiliated. The diagnoses
of VWD types 1, 2A, 2B, 2M and 3 were made as
reported elsewhere.2 Patients with VWD type 2M
Vicenza (2M VIC) were identified by the presence of
the typical supranormal multimers in plasma shown in
low resolution agarose gel electrophoresis. These
patients were enrolled in three Hemophilia Centers in
northern Italy and were also characterized by VWF
mutations as reported elsewhere.17,18 Patients with
VWD type 2M VIC were still classified as having
VWD type 2 following previous Italian recommenda-
tions,1,2 even though the most updated VWD classifi-
cation suggests that these particular patients should
be included among the type 1 group.19 
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Data on 100 VWD patients (44 males and 56 females,
median age 41.5, range 2-87 years) could be retrieved
for the study period. All patients were aware of the
nature of this retrospective survey and gave their
informed consent according to the Declaration of
Helsinki (1964).  
Management of VWD 
All patients were treated with bolus injections of
VWF/FVIII concentrate in the case of bleeds, surgery or
secondary long-term prophylaxis. The dosing regimens
of Haemate® P used were decided by each investigator
on the basis of the AICE’s recommendations.2 These are
expressed in units of FVIII because in Italy all concen-
trates are still labeled in terms of FVIII content only.
However, to allow us to compare our data with those
from other studies on Haemate® P previously reported
in the literature, we chose to express the dosage of the
study concentrate as VWF:RCo units, calculated from
an analysis of the batches used (average
VWF:RCo/FVIII:C ratio of 2.4). 
Distribution of patients enrolled by the various
Centers differed, each Center contributing a median of
six patients (range 2–26). As could be expected, the
three largest Centers enrolled 63% of the entire VWD
population. 
Bleeds were defined by site, such as epistaxis, gas-
trointestinal tract, gums, hemarthrosis, hematomas,
menorrhagia, or of traumatic nature. Cases of bleeding
involving more than one site or located in unusual sites
were defined, respectively, as at multiple sites and in other
sites. Surgery was divided according to the potential
bleeding risk of the procedures: major surgery (tho-
racic/abdominal surgery, obstetric/gynecological sur-
gery, orthopedic surgery, endocrine surgery and vascular
surgery), minor surgery (minor surgical interventions,
ophthalmic, skin, and ear, nose and throat [ENT] sur-
gery), oral surgery and invasive procedures. The pre-
operative dose of Haemate® P was administered 1 hour
before surgery. Twelve patients were included in a pro-
gram of secondary long-term prophylaxis because of
recurrent (at least three times) bleeds at the same sites,
mainly in the gastrointestinal tract or in the joints. 
The distribution of conditions requiring treatment
among the ten Hemophilia Centers showed a median
(range) numbers of bleeds, surgery and secondary long-
term prophylaxis of 17 (0-114), 6.5 (0–19) and 2 (0–4)
respectively. 
Assessment of efficacy and safety
Bleeding episodes and adverse drug reactions possibly
occurring in association with the treatment were
recorded using standardized data sheets. The efficacy of
the study drug in achieving hemostasis was evaluated
according to the following criteria: hemostasis clinically
not different from normal (excellent), mildly abnormal
hemostasis partial or delayed control of spontaneous
bleeding or slight transient oozing from surgical
wounds (good),  moderately abnormal hemostasis
bleeding not fully controlled but no need for additional
therapy (moderate); and no improvement at all with
continuation of bleeding and need for additional or
alternative therapies (poor). Adverse events were
defined as any change from baseline in the patient’s
health status that occurred within 24 hours of the
administration of Haemate® P, regardless of the poten-
tial relationship to the study product. Adverse events
related to surgery (post-operative nausea, vomiting,
fever and/or pain) were not considered to be possibly or
probably related to concentrate treatment and were not
included as adverse events in this study. In the case of
repeated administrations of Haemate® P during the
post-operative period or secondary long-term prophy-
laxis, FVIII:C levels were measured in most patients. If
FVIII:C levels were >180 IU/dL,  the following injection
of Haemate® P was postponed by 24 hours.  
Statistical analysis 
All study variables are summarized by descriptive sta-
tistics (i.e. mean, range and standard deviation) with
various subgroup analyses (e.g. demographics, VWD
types, indications for use). 
Results
Demographic data of the cohort of VWD patients 
Among the 100 VWD patients enrolled, 23 had type 1
VWD, 40 had type 2 (2A=7, 2B=11, 2M=9, 2M VIC= 13)
and 37 had type 3. Seventy-one percent had clinically
severe disease, as shown by VWF:RCo levels <10 IU/dL.
Age at first exposure and number of days of exposure to
VWF/FVIII concentrate were respectively lower and
higher in patients with VWD type 3 than in those with
other types (Table 1). The features and clinical respons-
es of the VWD patients treated with Haemate® P for
bleeds, surgery and secondary long-term prophylaxis
are summarized in Table 2.  
Bleeds 
Fifty-nine patients were treated because of 280 bleeds
with 1,003 infusions of Haemate® P (total amount
infused = 5.66×106 IU of VWF:RCo) with a median daily
dose of 72 (range, 27-135) VWF:RCo IU/kg. The clinical
response was rated as excellent/good in 95% of
patients. Moderate responses were mostly observed in
one patient with VWD type 3 who experienced con-
comitant bleeds at two different sites on three occasions
(Table 2). A median number of 3 bleeding episodes
(range, 1–43) treated with Haemate® P was observed
during the 3 years of follow-up. The different types of
bleeds that occurred in patients with the various types
of VWD are shown in Figure 1. Hemarthroses,
hematomas, menorrhagia and bleeds after moderate or
A.B. Federici et al.
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major trauma were observed mainly in patients with
VWD type 3, characterized by low FVIII levels. On the
other hand, gastrointestinal bleeds were observed in all
VWD types characterized by low levels of VWF:RCo.
Out of the 59 patients treated for bleeding episodes
with Haemate® P, a group of 11 patients (19%) (type
3=7, type 2A=1, type 2B=1, type 2M=2) with a more
severe bleeding tendency was identified. These patients
were responsible for 179 (64%) events and for the use
of 4.06×106 IU VWF:RCo of study product (72% of the
total consumption for bleeds) with an average adminis-
tration of 101 VWF:RCo IU/kg/day (range 38-135). With
regards to the total consumption of Haemate® P in all
VWD patients, 2.4×106 U of VWF:RCo were used for
gastrointestinal bleeds and 1.2×106 for hemarthroses.  
Surgery 
Fifty-six patients underwent 73 surgical procedures.
Seventeen underwent major surgery (1 vascular, 5
orthopedic, 9 thoracic-abdominal, 2 obstetric/gynecol-
ogical), 28 had minor surgery (1 ENT, 1 endocrine, 3
skin, 4 eye, 3 orthopedic, 6 obstetric/gynecological, 3
abdominal, 7 others), 9 underwent invasive procedures
and 19 had dental procedures, with a total consumption
of 1.97×106 IU of VWF:RCo in 366 infusions of
Haemate® P. The median daily dose was 80 (range, 27-
146) VWF:RCo IU/kg, with clinical responses rated as
excellent/good in 97% of patients (Table 2). The types
and sites of invasive and surgical procedures are shown
in Figure 2 while their number according to the VWD
type together with the use of Haemate® P by type of
procedure are summarized in Table 3. Overall, patients
undergoing major surgery received higher loading and
maintenance doses, more infusions and were treated for
more days than those exposed to minor surgery, oral
surgery or other invasive procedures. Efficacy was rated
as excellent/good in all but two procedures (97%)
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Table 1. Demographic data and clinical and laboratory parameters (median and range) of the 100 VWD patients enrolled in the retro-
spective study. 
Parameters Type 1 Type 2A Type 2B Type 2M Type 2MVIC Type 3 Total VWD
(n=23) (n=7) (n=11) (n=9) (n=13) (n=37) (n=100)
Sex (male/female) 8/15 5/2 3/8 6/3 7/6 15/22 44/56
Age (years)* 45(14-73) 60 (19-84) 58 (9-75) 46 (16-80) 57 (2-87) 23 (4-76) 41 (2-87)
Weight (Kg)* 70 (48-97) 72 (55-78) 65 (36-87) 74 (50-107) 72 (13-90) 64 (19-120) 66 (13-120)
VWF:RCo (U/dL)* 28 (3-47) 3 (3-15) 23 (10-39) 10 (5-47) 3 (3-9) < 3 3 (<3-47)
VWF:Ag (U/dL)* 29 (3-61) 27 (5-47) 54 (25-72) 29 (12-74) 7 (5-13) < 3 7 (<3-74)
FVIII:C (U/dL)* 53 (7-118) 42 (12-67) 56 (28-99) 55 (35-105) 18 (9-31) 5 (1-25) 24 (1-118)
Bleeding time (min)* 12 (5-35) 20 (6-35) 18 (9-27) 20 (12-35) 10 (5-25) 27 (9-35) 15 (5-35)
N. of patients with 39 71 9 67 100 100 71
severe VWD (%) 
(VWF:RCo < 10 IU/dL)*
Blood group (%)
O 22 17 14 40 28 29 26
Non-O 78 83 86 60 72 71 74
Age at first exposure to 40 (7-73) 37 (6-79) 33 (5-71) 46 (16-80) 48 (2-87) 11 (1-76) 26 (1-87)
VWF concentrates (years)* 
Days of exposure to
VWF concentrates (%)
0- 4 32 14 9 23 30 3 17
5-24 46 43 55 44 54 30 42
25-50 18 14 − − 8 6 8
51-150 − 15 18 − 8 18 11
> 150 4 14 18 33 − 43 22
*Results are expressed as median (min-max).
Table 2. Features and clinical responses of VWD patients treated
with Haemate®P for bleeds, surgery, and as secondary long-term
prophylaxis. 
Parameters Bleedings Surgeries Prophylaxis
Number of patients 59 56 12
Sex (male/female) 30/29 24/32 6/6
Age (years)* 31 (2-80) 42 (2-87) 35 (11-71)
Weight (kg)* 68 (13-120) 69 (13-120) 68 (28-90)
von Willebrand’s disease
Type 1 7 (12%) 19 (34%) 1 (8%)
Type 2A 3 (5%) 5 (9%) −
Type 2B 6 (10%) 6 (11%) 1 (8%)
Type 2M 6 (10%) 5 (9%) −
Type 2M VIC 5 (9%) 11 (19%) 1 (8%)
Type 3 32 (54%) 10 (18%) 9 (76%)
N. of pts with severe VWD 80% 64% 92% 
(VWF:RCo < 10 IU/dL)
Number of events 280 73 17
Number of infusions 1,003 366 1,424
Total VWF:RCo IU 5,665,000 1,970,000 5,601,000
VWF:RCo IU/kg/day* 72 (27-135) 80 (27-146) 72 (24-96)
Clinical response
excellent/good 95 97 100
moderate/poor 5 3 0
*Results are expressed as median (min-max).
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which were complicated by post-operative bleeding (1
pelvic hematoma and 1 episode of melena). A large
amount of Haemate® P (177600 IU VWF:RCo, 146
IU/kg/day) was used during spinal surgery in one 11-
year old patient. Only two patients were transfused
with red blood cells and one other patient received both
fresh-frozen plasma and platelet concentrates. These
three patients underwent major surgical interventions.
Twenty-one patients also received additional drugs
affecting hemostasis: tranexamic acid in 18 cases,
desmopressin in one case, and unfractionated heparin or
low molecular weight heparin in two cases.  
Secondary long-term prophylaxis 
Twelve patients (type 1=1, type 2B=1, type 2M
VIC=1, type 3=9, with a median age of 34.5 years; range
11-71) also received 17 long-term secondary prophylax-
is regimens to prevent recurrent bleedings at the same
site (47% in the gastrointestinal tract, 35% in joints).
Patients received 5.60×106 IU VWF:RCo in 1,424 infu-
sions of Haemate® P given three times (53.0%) or twice
(47.0%) a week, with clinical responses rated as excel-
lent/good response in 100%. Among patients receiving
prophylaxis, 70% had VWD type 3 and received 54%
of the overall product infused (Table 4). During the
4,358 days of prophylaxis (median 201; range, 30-730)
only four bleeding episodes were observed.  
Safety of Haemate® P 
Haemate® P was well tolerated and no adverse drug
reactions or thrombotic episodes were observed follow-
ing infusions. FVIII levels before and after each infusion
during repeated administration of Haemate® P for sur-
gery and secondary long-term prophylaxis were meas-
ured and were always below 180 IU/dL.  
Discussion 
Despite the fact that VWD is the most prevalent
inherited bleeding disorder,2 relatively few retrospective
or prospective data are available in literature describing
the efficacy and safety of plasma VWF concentrates in
patients with this disease. In this large retrospective
study, we report the efficacy and safety of Haemate® P
administered for bleeds, surgery and secondary long-
term prophylaxis over a period of 36 months in 100
well-characterized patients with inherited VWD at ten
Italian Hemophilia Centers. This is the largest retro-
spective survey in Italy on the clinical use of a
VWF/FVIII concentrate after the introduction of the rec-
ommendations on VWD diagnosis and therapy pub-
lished in the guidelines approved by the Italian
Association of Hemophilia Centers (AICE).2 The num-
ber of patients analyzed is also higher than that includ-
ed in the Canadian study on the same VWF/FVIII con-
centrate, which also enrolled patients with acquired von
Willebrand syndrome.13 Our cohort of patients included
mainly cases with severe disease. There is a higher
number of VWD type 2 and 3, as demonstrated by the
relatively high frequency of cases with basal VWF:RCo
levels <10 IU/dL. Among these, a relatively high per-
centage of patients with VWD type 2M VIC were
enrolled in the study at three Hemophilia Centers in
northern Italy. Therefore, it is not surprising that spon-
taneous bleeds such as hemarthroses, hematomas, epis-
taxis, menorrhagia and gastrointestinal bleeding
A.B. Federici et al.
Figure 1. Bleeding sites
according to type of VWD. 
Figure 2. Types and sites of invasive procedures or surgery. Minor
and major surgical procedures are indicated in white and gray hor-
izontal bars, respectively.  
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occurred relatively frequently. In the group of patients
treated with Haemate® P for bleeds, we identified a
group of 11/59 (19%) patients who were responsible for
179 (64%) bleeding events and for the use of 4.06×106 IU
VWF:RCo. Excellent or good responses were recorded
in 95% of these 59 VWD cases for 280 bleeding events,
a result which agrees with previously reported rates.13,16
Age does not seem to affect the clinical response to
Haemate® P, since a 95% rate of excellent/good respons-
es was observed not only in the general population of
59 cases, but also in the subgroup of 12 patients aged
under 14 years of age. Large amounts of Haemate® P
were used for gastrointestinal bleeds and hemarthroses
which usually require prolonged on-demand treatment.
Most of the VWD patients whose episodes of gastroin-
testinal bleeds and hemarthroses tended to recur were
allocated to secondary long-term prophylaxis (see
below). The efficacy and safety of Haemate® P were also
observed in 56 patients undergoing major or minor sur-
gery or other invasive procedures. Replacement therapy
with Haemate® P showed a good to excellent clinical
efficacy in 97% of cases. This agrees with results of pre-
vious retrospective studies.13-16 These findings also sup-
port the safety and efficacy of the VWF/FVIII concen-
trate Haemate® P when administered in doses based
upon VWF:RCo units. Other recent studies included a
retrospective analysis of the efficacy and safety of
Haemate® P in preventing bleeding during surgery or
invasive procedures,14 and a prospective, multicenter,
open-label, non-randomized study was conducted in
the USA on the use of Haemate® P in emergency surgi-
cal procedures.16
Whereas prophylaxis in hemophilia has become
widespread, this management strategy is used only
occasionally in VWD. There has been a recent report on
the results from a long-term prophylaxis experience in
Sweden20 in which 37 patients were treated for a medi-
an of 11 years (range 2-45). The majority of patients
(n=28) had type 3 VWD. The concentrate used in the
Swedish study since the mid 1980s was Haemate® P,
with a mean dose of 24 units factor VIII:C/kg body
weight given 1-3 times weekly. Other clinical informa-
tion on secondary long-term prophylaxis in VWD has
also been recently collected by a single Italian Center.21
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Table 3. Type of surgery and invasive procedures according to VWD types and the use of Haemate® P according to the type of inter-
vention.
Intervention VWD type
Total dose Daily dose Days of Days of Number of
Type 1 Type 2A Type 2B Type 2M Type 2M VIC Type 3 IU VWF:RCo IUVWF:RCo/kg/day hospitalization treatment infusions
(*) (**)
Major surgery 3 1 1 3 3 6 57,600 96 8 7 7 
(n=17) (17.6) (5.9) (5.9) (17.6) (17.6) (35.3) (14,400-177,600) (53-146) (6-18) (2-18) (2-18)
Minor surgery 8 2 5 5 2 6 16,800 71 1 3 3
(n=28) (28.6) (7.1) (17.9) (17.9) (7.1) (21.4) (4,800-55,200)  (32-120) (1-10) (1-11) (1-10)
Dental procedures 8 4 1 3 2 1 7,200 74 0 1 1 
(n=19) (42.1) (21.0) (5.3) (15.8) (10.5) (5.3) (2,400-21,600) (27-124) (0-3) (1-5) (1-5)
Invasive procedures 4 0 1 1 3 0 7,200 76 0 1 1 
(n=9) (44.5) (11.1) (11.1) (33.3) (3,600-28,800) (47-111) (0-7) (1-5) (1-5)
Total 23 7 8 12 10 13 6,800 80 1 3 3
(n=73) (31.5) (9.6) (11.0) (16.4) (17.8 ) (13.7) (2,400-177,600) (27-146) (0-18) (1-18) (1-18)
(*)results are expressed as No. cases (percentage) (**)results are expressed as median (min-max).
Table 4. Features and responses of VWD patients treated with
Haemate® P as prophylaxis.
Prophylaxis Gastrointestinal Joints Other
bleeds bleeds
Number of patients 5 4 3
Sex (male/female) 2/3 2/2 2/1
Age (years)* 59 (71-56) 42 (2-87) 35 (11-71)
Weight (kg)* 70 (48-90) 68 (36-78) 50 (28-70)
Number of cycles 8 6 3
Duration (days)* 230 (92-730) 269 (30-365) 60 (36-730)
Total VWF:RCo IU 3,024,000 1,357,000 826,000
VWF:RCo IU/kg/day* 60 (24-96) 72 (69-72) 86 (72-96)
Cycles vs
(infusion/week)
Type 1 1 (2/wk) − −
Type 2B 1 (3/wk) − −
Type 2M VIC 3 (3/wk) − −
Type 3 1 (3-2/wk) 4 (2/wk) 1 (2/wk)
Type 3 1 (2/wk) 2 (3/wk) 2 (3/wk)
Type 3 1 (3/wk) − −
Clinical response
excellent/good 100 100 100
moderate/poor − − −
*Results are expressed as median (min-max).
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In this retrospective study clinical data were collected
on 17 cycles of secondary long-term prophylaxis admin-
istered to 12 patients with VWD type 3 and in two
other patients mainly because of gastrointestinal bleed-
ing and hemarthroses. As in the previous study, this
approach seemed to be very promising as shown by the
100% excellent clinical responses and the reduction in
days of hospitalization for blood transfusions with
packed red cells.21 However, prospective studies aimed
at evaluating the cost/benefit ratio of secondary long-
term prophylaxis are required before recommending
this approach in current clinical practice. A large amount
of Haemate® P was used within 36 months, in 59 cases
for bleeds  (5.7×106 VWF:RCo IU), in 56 cases for sur-
gery (1.97×106 VWF:RCo IU) and in 12 cases for second-
ary long-term prophylaxis (5.6×106 VWF:RCo IU). We
observed a trend to a relatively higher consumption,
measured as VWF:RCo Units/Kg body weight, com-
pared to that in other previously reported retrospective
studies. This may be explained by the high proportion
of patients with severe VWD in our cohort (71%) and
by the fact that Haemate® P and other VWF/FVIII con-
centrates in Italy are still labeled in FVIII activity units,
and not as VWF:RCo. This might have led to the use of
more concentrate than necessary. However, the expres-
sion of results in VWF:RCo IU was useful to compare
our findings with those reported in the USA and
Canada. This emphasizes once more the importance of
dosing VWF/FVIII concentrates according to VWF:RCo
units and of measuring FVIII before and after every
injection to evaluate the secondary response that also
includes the endogenous production of FVIII in VWD
patients. 
Despite the fact that some patients received more
than 100 IU/kg of VWF:RCo with repeated infusions to
stop bleeding, during surgery or for long-term prophy-
laxis, no major side effects, including thrombosis, were
reported. During this study, FVIII levels after each
administration during repeated infusions of Haemate® P,
especially during surgery, were not higher than 180
UI/dL. These data certainly suggest that unnecessary
higher levels of FVIII can be avoided simply by assaying
FVIII before any additional repeated treatment and that
the frequency of administration of Haemate® P should
be reduced when FVIII levels are higher than 150 UI/dL. 
In conclusion, our retrospective analysis provides fur-
ther evidence supporting the safety and efficacy of
Haemate® P as on-demand treatment for the manage-
ment of bleeding episodes and to prevent bleeding dur-
ing surgery, as well as for secondary long-term prophy-
laxis to prevent recurrent bleeding in VWD patients.  
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